| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Eli Gilboa | |
| P2860 | cites work | alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity | Q80516665 |
| Knocking the SOCS1 off dendritic cells | Q81105362 | ||
| Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency | Q81307106 | ||
| Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer | Q81482708 | ||
| GILZ expression in human dendritic cells redirects their maturation and prevents antigen-specific T lymphocyte response | Q81491673 | ||
| Professional antigen-presentation function by human gammadelta T Cells | Q81810232 | ||
| Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo | Q82828413 | ||
| CD40 AND CD154 IN CELL-MEDIATED IMMUNITY | Q22255634 | ||
| Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling | Q24684997 | ||
| Dendritic cells and the control of immunity | Q27860918 | ||
| Pathogen recognition and innate immunity | Q27861084 | ||
| The CD40/CD154 receptor/ligand dyad | Q28202756 | ||
| Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? | Q28207052 | ||
| TNF/TNFR family members in costimulation of T cell responses | Q28240053 | ||
| Cancer despite immunosurveillance: immunoselection and immunosubversion | Q28263865 | ||
| Toll-like receptor control of the adaptive immune responses | Q29547305 | ||
| Immunobiology of dendritic cells | Q29547465 | ||
| Exosomes: composition, biogenesis and function | Q29547721 | ||
| Immunosuppressive networks in the tumour environment and their therapeutic relevance | Q29619244 | ||
| Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor | Q29619247 | ||
| Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes | Q29619437 | ||
| Antigen density presented by dendritic cells in vivo differentially affects the number and avidity of primary, memory, and recall CD8+ T cells. | Q30310494 | ||
| Expression library immunization to discover and improve vaccine antigens | Q30833383 | ||
| Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: implications for generating CD8+ T cell responses to infectious agents, tumors, transplants, and vaccines | Q33683185 | ||
| Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens | Q33714644 | ||
| The makings of a tumor rejection antigen | Q33748013 | ||
| Dendritic-cell trafficking to lymph nodes through lymphatic vessels | Q33989067 | ||
| Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells | Q34141893 | ||
| Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells | Q34147162 | ||
| Viral vectors for dendritic cell-based immunotherapy | Q34207596 | ||
| The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity | Q34232543 | ||
| Dendritic cells as sensors of infection. | Q34260225 | ||
| Killing of dendritic cells: a life cut short or a purposeful death? | Q34355697 | ||
| Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors | Q34787754 | ||
| Direct stimulation of T cells by membrane vesicles from antigen-presenting cells | Q34984478 | ||
| Dendritic cells under the spell of prostaglandins | Q35077130 | ||
| The use of dendritic cells in cancer immunotherapy | Q35084257 | ||
| Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins | Q35108258 | ||
| Clinical applications of dendritic cell vaccination in the treatment of cancer | Q35597274 | ||
| Manipulating dendritic cell biology for the active immunotherapy of cancer | Q35825249 | ||
| Targeting plasmid-encoded proteins to the antigen presentation pathways | Q35826370 | ||
| Cancer immunotherapy with mRNA-transfected dendritic cells | Q35826417 | ||
| B lymphocytes as antigen-presenting cell-based genetic vaccines | Q35826422 | ||
| Dendritic cell-based vaccines in cancer immunotherapy: an update on clinical and immunological results. | Q35914669 | ||
| Transfer of antigen between migrating and lymph node-resident DCs in peripheral T-cell tolerance and immunity | Q35941910 | ||
| Regulation of antigen presentation and cross-presentation in the dendritic cell network: facts, hypothesis, and immunological implications. | Q36037772 | ||
| Dendritic-cell-based therapeutic vaccination against cancer | Q36070700 | ||
| Migration of dendritic cell based cancer vaccines: in vivo veritas? | Q36070704 | ||
| Dendritic cells as therapeutic vaccines against cancer | Q36085614 | ||
| Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL | Q36367150 | ||
| Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming | Q36371607 | ||
| Negative selection during the peripheral immune response to antigen | Q36376090 | ||
| Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T lymphocyte-induced apoptosis: differential modulation by T helper type 1 and type 2 cells | Q36376315 | ||
| Immune regulation in tumor-bearing hosts | Q36390008 | ||
| A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. | Q36403615 | ||
| An inverse relationship between T cell receptor affinity and antigen dose during CD4(+) T cell responses in vivo and in vitro | Q36433369 | ||
| Checkpoint blockade in cancer immunotherapy | Q36490768 | ||
| On regulation of phagosome maturation and antigen presentation | Q36598303 | ||
| Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells | Q37139993 | ||
| Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. | Q37629901 | ||
| Experimental and clinical studies with active specific immunotherapy | Q38628391 | ||
| Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. | Q40357536 | ||
| Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand. | Q40477269 | ||
| Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity | Q40488939 | ||
| Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation | Q40614046 | ||
| Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes | Q40668644 | ||
| Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells | Q40701084 | ||
| Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells | Q40753335 | ||
| Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. | Q40856900 | ||
| High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. | Q40978441 | ||
| Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. | Q41049213 | ||
| Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients | Q42742001 | ||
| Stimulation history dictates memory CD8 T cell phenotype: implications for prime-boost vaccination | Q43725424 | ||
| Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets | Q44083646 | ||
| Therapeutic dendritic-cell vaccine for simian AIDS. | Q44259259 | ||
| Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors | Q44394548 | ||
| Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism | Q44555982 | ||
| Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells | Q44662354 | ||
| Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity | Q45027178 | ||
| Therapeutic dendritic-cell vaccine for chronic HIV-1 infection | Q45165349 | ||
| Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model | Q45429014 | ||
| Optimization of the sequence of antigen loading and CD40-ligand-induced maturation of dendritic cells | Q47783881 | ||
| Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells | Q47938199 | ||
| Immunology. Licence to kill | Q47982772 | ||
| Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting defined RNAs after rather than before maturation. | Q50777089 | ||
| Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo. | Q51550263 | ||
| Long-lived memory CD8+ T cells are programmed by prolonged antigen exposure and low levels of cellular activation. | Q51983937 | ||
| Both dendritic cells and macrophages can stimulate naive CD8 T cells in vivo to proliferate, develop effector function, and differentiate into memory cells. | Q51989826 | ||
| Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses. | Q51991421 | ||
| Differing roles of inflammation and antigen in T cell proliferation and memory generation. | Q52022095 | ||
| Final maturation of dendritic cells is associated with impaired responsiveness to IFN-gamma and to bacterial IL-12 inducers: decreased ability of mature dendritic cells to produce IL-12 during the interaction with Th cells. | Q54102042 | ||
| Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. | Q55043174 | ||
| Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function | Q56880717 | ||
| Paralysis of Dendritic Cell IL-12 Production by Microbial Products Prevents Infection-Induced Immunopathology | Q56880739 | ||
| Human Dendritic Cells Transfected with RNA Encoding Prostate-Specific Antigen Stimulate Prostate-Specific CTL Responses In Vitro | Q56967620 | ||
| Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state | Q57779701 | ||
| Rapid Peptide Turnover and Inefficient Presentation of Exogenous Antigen Critically Limit the Activation of Self-Reactive CTL by Dendritic Cells | Q58235001 | ||
| IFN-α-conditioned dendritic cells are highly efficient in inducing cross-priming CD8+ T cells against exogenous viral antigens | Q58960918 | ||
| Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells | Q73035410 | ||
| Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions | Q74179201 | ||
| Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides | Q74314851 | ||
| Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity | Q77892680 | ||
| The DRiP hypothesis decennial: support, controversy, refinement and extension | Q79827462 | ||
| The promise of cancer vaccines | Q80038678 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1195-1203 | |
| P577 | publication date | 2007-05-01 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | DC-based cancer vaccines | |
| P478 | volume | 117 |
| Q39691738 | 1-MT enhances potency of tumor cell lysate-pulsed dendritic cells against pancreatic adenocarcinoma by downregulating the percentage of Tregs |
| Q90162116 | A Novel Model of Cancer Drug Resistance: Oncosomal Release of Cytotoxic and Antibody-Based Drugs |
| Q34755217 | A composite MyD88/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy |
| Q38206520 | A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs |
| Q37002959 | A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients |
| Q57184942 | A multifunctional core-shell nanoparticle for dendritic cell-based cancer immunotherapy |
| Q39338676 | A novel and simple method for generation of human dendritic cells from unfractionated peripheral blood mononuclear cells within 2 days: its application for induction of HIV-1-reactive CD4(+) T cells in the hu-PBL SCID mice |
| Q34015759 | A potential protein adjuvant derived from Mycobacterium tuberculosis Rv0652 enhances dendritic cells-based tumor immunotherapy |
| Q41867724 | A suppressor of cytokine signaling 1 antagonist enhances antigen-presenting capacity and tumor cell antigen-specific cytotoxic T lymphocyte responses by human monocyte-derived dendritic cells |
| Q35475233 | A view on dendritic cell immunotherapy in ovarian cancer: how far have we come? |
| Q33622752 | Abrogation of local cancer recurrence after radiofrequency ablation by dendritic cell-based hyperthermic tumor vaccine |
| Q34399608 | Activation of dendritic cells by the novel Toll-like receptor 3 agonist RGC100. |
| Q30300186 | Adenosine 2A receptors in acute kidney injury |
| Q44024646 | Ambivalent effects of dendritic cells displaying prostaglandin E2-induced indoleamine 2,3-dioxygenase |
| Q37189574 | An effective vaccine against colon cancer in mice: use of recombinant adenovirus interleukin-12 transduced dendritic cells |
| Q34533616 | An optimized method for manufacturing a clinical scale dendritic cell-based vaccine for the treatment of glioblastoma |
| Q64111710 | Anti-tumor outcome evaluation against non-small cell lung cancer in vitro and in vivo using PolyI:C as nucleic acid therapeutic agent |
| Q48564522 | Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens |
| Q36168490 | Antigenically Modified Human Pluripotent Stem Cells Generate Antigen-Presenting Dendritic Cells |
| Q39013263 | Antitumor effect of dendritic cell loaded ex vivo and in vivo with tumor-associated antigens in lung cancer model |
| Q34795079 | Bee Venom Phospholipase A2, a Good "Chauffeur" for Delivering Tumor Antigen to the MHC I and MHC II Peptide-Loading Compartments of the Dendritic Cells: The Case of NY-ESO-1. |
| Q37362981 | Behavior of immune players in the tumor microenvironment |
| Q38000520 | Biological applications of magnetic nanoparticles. |
| Q93103938 | Biomaterial-based platforms for in situ dendritic cell programming and their use in antitumor immunotherapy |
| Q55463511 | Biomaterial-based vaccine induces regression of established intracranial glioma in rats. |
| Q33393205 | Bone marrow-derived dendritic cells pulsed with tumor lysates induce anti-tumor immunity against gastric cancer ex vivo |
| Q37952245 | Brain cancer immunoediting: novel examples provided by immunotherapy of malignant gliomas |
| Q33864097 | CCL3 and CCL20-recruited dendritic cells modified by melanoma antigen gene-1 induce anti-tumor immunity against gastric cancer ex vivo and in vivo |
| Q34014497 | CD40-activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non-Hodgkin's lymphoma |
| Q50471175 | CD8(+) T-cell priming and boosting: more antigen-presenting DC, or more antigen per DC? |
| Q36255729 | Can dendritic cells improve whole cancer cell vaccines based on immunogenically killed cancer cells? |
| Q48319918 | Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs. |
| Q39958332 | Cancer immunotherapy. |
| Q37698219 | Cancer vaccine by fusions of dendritic and cancer cells |
| Q42384053 | Cancer vaccine development: designing tumor cells for greater immunogenicity |
| Q38366247 | Cancer-immune equilibrium: questions unanswered |
| Q34987106 | Carthamus tinctorius Enhances the Antitumor Activity of Dendritic Cell Vaccines via Polarization toward Th1 Cytokines and Increase of Cytotoxic T Lymphocytes |
| Q39398806 | Characterization of monocyte-derived dendritic cells from immunosuppressed renal transplant recipients with and without squamous cell carcinomas. |
| Q35534802 | Characterization of transglutaminase type II role in dendritic cell differentiation and function |
| Q35149637 | Classification of current anticancer immunotherapies |
| Q34658452 | Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go. |
| Q39117175 | Combinational delivery of lipid-enveloped polymeric nanoparticles carrying different peptides for anti-tumor immunotherapy |
| Q35802152 | Combined Tbet and IL12 gene therapy elicits and recruits superior antitumor immunity in vivo. |
| Q34231139 | Comparative Analysis of Cytotoxic T Lymphocyte Response Induced by Dendritic Cells Loaded with Hepatocellular Carcinoma -Derived RNA or Cell Lysate |
| Q39234940 | Comparison of clinical grade type 1 polarized and standard matured dendritic cells for cancer immunotherapy |
| Q43259670 | Comparison of monocyte-derived dendritic cells from colorectal cancer patients, non-small-cell-lung-cancer patients and healthy donors |
| Q61698866 | Comparison of α-Type-1 polarizing and standard dendritic cell cytokine cocktail for maturation of therapeutic monocyte-derived dendritic cell preparations from cancer patients |
| Q82458861 | Complete remission of mantle-cell non-Hodgkin lymphoma with a dendritic cell vaccine |
| Q84520481 | Conjugation of HPV16 E7 to cholera toxin enhances the HPV-specific T-cell recall responses to pulsed dendritic cells in vitro in women with cervical dysplasia |
| Q37568374 | CpG oligodeoxynucleotide as immune adjuvant enhances photodynamic therapy response in murine metastatic breast cancer |
| Q40239916 | Culture of myeloid dendritic cells from bone marrow precursors. |
| Q91497028 | Cytolytic Activity of Effector T-lymphocytes Against Hepatocellular Carcinoma is Improved by Dendritic Cells Pulsed with Pooled Tumor Antigens |
| Q37403716 | Cytosolic delivery mediated via electrostatic surface binding of protein, virus, or siRNA cargos to pH-responsive core-shell gel particles |
| Q40983895 | Cytotoxicity of tumor antigen specific human T cells is unimpaired by arginine depletion |
| Q47412496 | Defining a standard and weighted mathematical index for maturation of dendritic cells. |
| Q52866914 | Delivery of Synthetic mRNA Encoding FOXP3 Antigen into Dendritic Cells for Inflammatory Breast Cancer Immunotherapy. |
| Q34284652 | Dendritic Cell‐Based Immunotherapy for Prostate Cancer |
| Q38031280 | Dendritic cell engineering for tumor immunotherapy: from biology to clinical translation |
| Q34291122 | Dendritic cell immunotherapy in uterine cancer. |
| Q36140598 | Dendritic cell preactivation impairs MHC class II presentation of vaccines and endogenous viral antigens |
| Q64990202 | Dendritic cell vaccine with Ag85A enhances anti-colorectal carcinoma immunity. |
| Q37971324 | Dendritic cell vaccines in cancer immunotherapy: from biology to translational medicine |
| Q37259624 | Dendritic cell-based cancer vaccination: quo vadis? |
| Q37554417 | Dendritic cell-based immunotherapy in ovarian cancer |
| Q90326818 | Dendritic cell-based vaccination: powerful resources of immature dendritic cells against pancreatic adenocarcinoma |
| Q37773259 | Dendritic cell-based vaccines for the therapy of experimental tumors |
| Q35790418 | Dendritic cells as danger-recognizing biosensors |
| Q39842438 | Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy |
| Q30422946 | Dendritic cells in acute kidney injury: cues from the microenvironment |
| Q91584638 | Dendritic cells loaded with CD44+ CT-26 colon cell lysate evoke potent antitumor immune responses |
| Q34055365 | Dendritic cells loaded with tumor B cells elicit broad immunity against murine gammaherpesvirus 68 but fail to prevent long-term latency |
| Q33614807 | Dendritic cells pulsed with keyhole limpet hemocyanin and cryopreserved maintain anti-tumor activity in a murine melanoma model |
| Q38002844 | Dendritic cells the tumor microenvironment and the challenges for an effective antitumor vaccination |
| Q30318566 | Dendritic cells transfected with Her2 antigen-encoding RNA replicons cross-prime CD8 T cells and protect mice against tumor challenge |
| Q43906358 | Dendritic cells transfected with PEG10 recombinant adenovirus elicit anti-tumor immune response in vitro and in vivo |
| Q39020907 | Dendritic cells: In vitro culture in two- and three-dimensional collagen systems and expression of collagen receptors in tumors and atherosclerotic microenvironments. |
| Q36823321 | Differentiation of two types of mobilized peripheral blood stem cells by microRNA and cDNA expression analysis |
| Q36038717 | Disruption of the SapM locus in Mycobacterium bovis BCG improves its protective efficacy as a vaccine against M. tuberculosis |
| Q87623029 | Downregulation of endogenous STAT3 augments tumoricidal activity of interleukin 15 activated dendritic cell against lymphoma and leukemia via TRAIL |
| Q41937286 | Dual signaling of MyD88 and TRIF is critical for maximal TLR4-induced dendritic cell maturation |
| Q90290795 | Editorial: Combinatorial Approaches to Enhance Anti-tumor Immunity: Focus on Immune Checkpoint Blockade Therapy |
| Q34658123 | Effect of ex vivo culture duration on phenotype and cytokine production by mature dendritic cells derived from peripheral blood monocytes |
| Q38649472 | Effect of oxygen levels on the physiology of dendritic cells: implications for adoptive cell therapy |
| Q50130525 | Efficacy of intracellular immune checkpoint-silenced DC vaccine |
| Q34020065 | Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma |
| Q92446089 | Engineered Nanodelivery Systems to Improve DNA Vaccine Technologies |
| Q38051671 | Engineered dendritic cells for gastrointestinal tumor immunotherapy: opportunities in translational research |
| Q37862064 | Engineering dendritic cells to enhance cancer immunotherapy |
| Q28749647 | Engulfing tumors with synthetic extracellular matrices for cancer immunotherapy |
| Q42255825 | Enhanced antitumor immunotherapeutic effect of B-cell-based vaccine transduced with modified adenoviral vector containing type 35 fiber structures |
| Q47649487 | Enhanced cytotoxic activity of effector T-cells against cholangiocarcinoma by dendritic cells pulsed with pooled mRNA. |
| Q38672403 | Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon-γ and multiple toll-like receptor agonists. |
| Q47214177 | EpCAM peptide-primed dendritic cell vaccination confers significant anti-tumor immunity in hepatocellular carcinoma cells |
| Q33705361 | Evaluation of 3 clinical dendritic cell maturation protocols containing lipopolysaccharide and interferon-gamma |
| Q33347561 | Ex vivo recovery and activation of dysfunctional, anergic, monocyte-derived dendritic cells from patients with operable breast cancer: critical role of IFN-alpha |
| Q59135320 | Exosomes derived from rAAV/AFP-transfected dendritic cells elicit specific T cell-mediated immune responses against hepatocellular carcinoma |
| Q35138155 | Exploitation of Langerhans cells for in vivo DNA vaccine delivery into the lymph nodes. |
| Q38148774 | Exploiting dendritic cells in the development of cancer vaccines |
| Q34490196 | Expression of ESE-3 isoforms in immunogenic and tolerogenic human monocyte-derived dendritic cells |
| Q33951651 | FRET microscopy autologous tumor lysate processing in mature dendritic cell vaccine therapy |
| Q87957089 | Functional ferritin nanoparticles for biomedical applications |
| Q35625349 | Gastric cancer and the epoch of immunotherapy approaches |
| Q34443707 | Gene carriers and transfection systems used in the recombination of dendritic cells for effective cancer immunotherapy |
| Q37173478 | Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs. |
| Q40082714 | Generation of a prophylactic melanoma vaccine using whole recombinant yeast expressing MART-1. |
| Q37959362 | Generation of immunogenic and tolerogenic clinical-grade dendritic cells |
| Q38713382 | Generation of potent cytotoxic T lymphocytes against in male patients with non-muscle invasive bladder cancer by dendritic cells loaded with dying T24 bladder cancer cells |
| Q36756884 | Genetic Immunization With In Vivo Dendritic Cell-targeting Liposomal DNA Vaccine Carrier Induces Long-lasting Antitumor Immune Response |
| Q37800934 | Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow? |
| Q44294226 | HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines. |
| Q35556207 | HER2-based recombinant immunogen to target DCs through FcγRs for cancer immunotherapy. |
| Q38000158 | HPK1 as a novel target for cancer immunotherapy |
| Q64071651 | Harnessing Dendritic Cells for Poly (D,L-lactide--glycolide) Microspheres (PLGA MS)-Mediated Anti-tumor Therapy |
| Q36809755 | Harnessing the immune system to treat cancer |
| Q26797410 | Heparan Sulfate Proteoglycan Metabolism and the Fate of Grafted Tissues |
| Q42751318 | High-level antigen expression and sustained antigen presentation in dendritic cells nucleofected with wild-type viral mRNA but not DNA. |
| Q92626019 | Honokiol-enhanced cytotoxic T lymphocyte activity against cholangiocarcinoma cells mediated by dendritic cells pulsed with damage-associated molecular patterns |
| Q39003419 | Human Dendritic Cell-Derived Induced Pluripotent Stem Cell Lines Are Not Immunogenic. |
| Q34152633 | Human IP10-scFv and DC-induced CTL synergistically inhibit the growth of glioma in a xenograft model |
| Q41587909 | Human dendritic cell activation induced by a permannosylated dendron containing an antigenic GM3-lactone mimetic. |
| Q37035660 | Human parainfluenza virus type 2 vector induces dendritic cell maturation without viral RNA replication/transcription |
| Q30436422 | Identification of a 17beta-hydroxysteroid dehydrogenase type 12 pseudogene as the source of a highly restricted BALB/c Meth A tumor rejection peptide |
| Q37649282 | Identification of immune factors regulating antitumor immunity using polymeric vaccines with multiple adjuvants |
| Q37728918 | Identification of novel HLA-A*0201-restricted epitopes from anterior gradient-2 as a tumor-associated antigen against colorectal cancer |
| Q26747061 | Immune Cells in Cancer Therapy and Drug Delivery |
| Q53092562 | Immune Monitoring Using mRNA-Transfected Dendritic Cells. |
| Q28076556 | Immune evasion pathways and the design of dendritic cell-based cancer vaccines |
| Q37211699 | Immune response, clinical outcome and safety of dendritic cell vaccine in combination with cytokine-induced killer cell therapy in cancer patients |
| Q33907609 | Immune tolerance induction by integrating innate and adaptive immune regulators |
| Q37560241 | Immune-maximizing (IMAX) therapy for cancer: Combination of dendritic cell vaccine and intensity-modulated radiation. |
| Q39788533 | Immunogenicity of allo-vesicle carrying ERBB2 tumor antigen for dendritic cell-based anti-tumor immunotherapy. |
| Q36498459 | Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients |
| Q35900294 | Immunological Characterization of Whole Tumour Lysate-Loaded Dendritic Cells for Cancer Immunotherapy |
| Q34898280 | Immunological and clinical effects of vaccines targeting p53-overexpressing malignancies |
| Q38078123 | Immunoregulatory properties of rapamycin-conditioned monocyte-derived dendritic cells and their role in transplantation |
| Q26866513 | Immunotherapy advances for glioblastoma |
| Q100425524 | Immunotherapy for Metastatic Prostate Cancer: Current and Emerging Treatment Options |
| Q37140636 | Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines |
| Q37971408 | Immunotherapy targeting glioma stem cells--insights and perspectives |
| Q55023877 | Impact of 5-Fu/oxaliplatin on mouse dendritic cells and synergetic effect with a colon cancer vaccine. |
| Q35573167 | In Vivo Modulation of Dendritic Cells by Engineered Materials: Towards New Cancer Vaccines. |
| Q34330250 | In situ modulation of dendritic cells by injectable thermosensitive hydrogels for cancer vaccines in mice |
| Q39885761 | In situ regulation of DC subsets and T cells mediates tumor regression in mice |
| Q37314596 | In vivo dendritic cell tracking using fluorescence lifetime imaging and near-infrared-emissive polymersomes |
| Q37822291 | In vivo imaging of immune cell trafficking in cancer |
| Q43874189 | In vivo imaging of lymph node migration of MNP- and (111)In-labeled dendritic cells in a transgenic mouse model of breast cancer (MMTV-Ras). |
| Q33767127 | In vivo trafficking and immunostimulatory potential of an intranasally-administered primary dendritic cell-based vaccine |
| Q36982907 | Increased TLR responses in dendritic cells lacking the ITAM-containing adapters DAP12 and FcRgamma |
| Q42261479 | Increased extracellular pressure provides a novel adjuvant stimulus for enhancement of conventional dendritic cell maturation strategies |
| Q47864145 | Increases in serum TARC/CCL17 levels are associated with progression-free survival in advanced melanoma patients in response to dendritic cell-based immunotherapy |
| Q82845503 | Induction of antigen-specific cytotoxic T lymphocytes by using monocyte-derived DCs transfected with in vitro-transcribed WT1 or SART1 mRNA |
| Q39896570 | Infection-mimicking materials to program dendritic cells in situ |
| Q37670964 | Inflammatory cytokines presented from polymer matrices differentially generate and activate DCs in situ. |
| Q40059574 | Inherent Immunogenicity or Lack Thereof of Pluripotent Stem Cells: Implications for Cell Replacement Therapy |
| Q41298079 | Inhibition of SIRPα in dendritic cells potentiates potent antitumor immunity |
| Q93170301 | Injectable Biodegradable Chitosan-Alginate 3D Porous Gel Scaffold for mRNA Vaccine Delivery |
| Q39550595 | Interleukin-12p70 expression by dendritic cells of HIV-1-infected patients fails to stimulate gag-specific immune responses |
| Q89135118 | Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes |
| Q36025111 | Isolation and generation of human dendritic cells |
| Q40042422 | Lactobacillus acidophilus could modulate the immune response against breast cancer in murine model |
| Q30413501 | Laser vaccine adjuvants. History, progress, and potential |
| Q58862004 | Long-lasting cross-presentation of tumor antigen in human DC |
| Q37262385 | Lymphoid-tissue-specific homing of bone-marrow-derived dendritic cells |
| Q33786246 | Maturation of monocyte derived dendritic cells with OK432 boosts IL-12p70 secretion and conveys strong T-cell responses. |
| Q36631270 | Methionine enkephalin (MENK) improved the functions of bone marrow-derived dendritic cells (BMDCs) loaded with antigen |
| Q37745683 | Mitochondria-centric activation induced cell death of cytolytic T lymphocytes and its implications for cancer immunotherapy. |
| Q39312666 | Modern strategies and capabilities for activation of the immune response against tumor cells |
| Q34588908 | Modular injectable matrices based on alginate solution/microsphere mixtures that gel in situ and co-deliver immunomodulatory factors |
| Q58701885 | Modulation of the Tumor Microenvironment by CXCR4 Antagonist-Armed Viral Oncotherapy Enhances the Antitumor Efficacy of Dendritic Cell Vaccines against Neuroblastoma in Syngeneic Mice |
| Q33738902 | Molecular signatures of maturing dendritic cells: implications for testing the quality of dendritic cell therapies |
| Q51673761 | NK Cell Activation in the Antitumor Response Induced by IFN-α Dendritic Cells Loaded with Apoptotic Cells from Follicular Lymphoma Patients. |
| Q38269126 | Nanoengineered strategies to optimize dendritic cells for gastrointestinal tumor immunotherapy: from biology to translational medicine |
| Q90628293 | Nanotherapeutics for Immuno-Oncology: A Crossroad for New Paradigms |
| Q35027661 | Natural killer T cells in advanced melanoma patients treated with tremelimumab |
| Q34590195 | Natural killer T cells play a necessary role in modulating of immune-mediated liver injury by gut microbiota |
| Q34357503 | Novel cancer vaccine based on genes of Salmonella pathogenicity island 2. |
| Q27011232 | Novel immunotherapeutic strategies of gastric cancer treatment |
| Q45967667 | OK-432 synergizes with IFN-γ to confer dendritic cells with enhanced antitumor immunity. |
| Q36085370 | Off-the-shelf adenoviral-mediated immunotherapy via bicistronic expression of tumor antigen and iMyD88/CD40 adjuvant |
| Q37171980 | Oncolytic virotherapy as a personalized cancer vaccine |
| Q47899915 | Optimization of Dendritic Cell-Mediated Cytotoxic T-Cell Activation by Tracking of Dendritic Cell Migration Using Reporter Gene Imaging |
| Q38832705 | Optimizing the process of nucleofection for professional antigen presenting cells |
| Q39717873 | Oral administration of myostatin-specific whole recombinant yeast Saccharomyces cerevisiae vaccine increases body weight and muscle composition in mice |
| Q34189694 | Overview of cellular immunotherapy for patients with glioblastoma. |
| Q36220691 | PD-1/PD-L1 blockade can enhance HIV-1 Gag-specific T cell immunity elicited by dendritic cell-directed lentiviral vaccines |
| Q37719552 | Patented cancer vaccines: the promising leads |
| Q45867029 | Phase I/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma. |
| Q45858586 | Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo |
| Q40427880 | Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials |
| Q37167802 | Polymer nanoparticles for cross-presentation of exogenous antigens and enhanced cytotoxic T-lymphocyte immune response |
| Q30409053 | Pre-immature dendritic cells (PIDC) pulsed with HPV16 E6 or E7 peptide are capable of eliciting specific immune response in patients with advanced cervical cancer |
| Q47172931 | Precision-porous templated scaffolds of varying pore size drive dendritic cell activation |
| Q39939540 | Prevention of both direct and cross-priming of antitumor CD8+ T-cell responses following overproduction of prostaglandin E2 by tumor cells in vivo |
| Q37158844 | Production of antibodies against multipass membrane proteins expressed in human tumor cells using dendritic cell immunization |
| Q57167306 | Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer |
| Q35693324 | Progression of Large Lymphoma Is Significantly Impeded with a Combination of Gemcitabine Chemotherapy and Dendritic Cells Intra-Tumor Vaccination |
| Q39665878 | Prolonged antigen storage endows merocytic dendritic cells with enhanced capacity to prime anti-tumor responses in tumor-bearing mice |
| Q34856875 | Prostate cancer as a model for tumour immunotherapy |
| Q39816081 | Protective anti-tumour immune responses by murine dendritic cells pulsed with recombinant Tat-carcinoembryonic antigen derived from Escherichia coli. |
| Q33384384 | Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction |
| Q34316777 | Quality assessment of cellular therapies: the emerging role of molecular assays |
| Q39300036 | RAFTsomes containing epitope-MHC-II complexes mediated CD4+ T cell activation and antigen-specific immune responses |
| Q37686532 | RNA as performance-enhancers for dendritic cells |
| Q34529895 | Rabies virus expressing dendritic cell-activating molecules enhances the innate and adaptive immune response to vaccination |
| Q38248440 | Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies |
| Q23918376 | Recognition of live phosphatidylserine-labeled tumor cells by dendritic cells: a novel approach to immunotherapy of skin cancer |
| Q34708479 | Recombinant mammaglobin A adenovirus-infected dendritic cells induce mammaglobin A-specific CD8+ cytotoxic T lymphocytes against breast cancer cells in vitro |
| Q49773390 | Recombinant rabies virus with the glycoprotein fused with a DC-binding peptide is an efficacious rabies vaccine |
| Q34735086 | Recombinant rabies viruses expressing GM-CSF or flagellin are effective vaccines for both intramuscular and oral immunizations. |
| Q33713903 | Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity |
| Q27025996 | Regulatory dendritic cell therapy: from rodents to clinical application |
| Q41963849 | Relationship of vaccine efficacy to the kinetics of DC and T-cell responses induced by PLG-based cancer vaccines |
| Q36645834 | Rhamnogalacturonan II is a Toll-like receptor 4 agonist that inhibits tumor growth by activating dendritic cell-mediated CD8+ T cells |
| Q36067874 | Safe and Reproducible Preparation of Functional Dendritic Cells for Immunotherapy in Glioblastoma Patients |
| Q37063739 | Signaling defects in anti-tumor T cells |
| Q39663885 | Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8+ T cell/regulatory T cells in tumour |
| Q39398295 | Simultaneous targeting of toll- and nod-like receptors induces effective tumor-specific immune responses |
| Q59335796 | Single-Cell Transcriptomics in Cancer Immunobiology: The Future of Precision Oncology |
| Q27334432 | Size-dependent effects of gold nanoparticles uptake on maturation and antitumor functions of human dendritic cells in vitro |
| Q35122102 | Specific microtubule-depolymerizing agents augment efficacy of dendritic cell-based cancer vaccines |
| Q64992567 | Stabilization of acute myeloid leukemia with a dendritic cell vaccine. |
| Q26823515 | Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy |
| Q53581193 | Study on the mesothelin-specific cytotoxicity against epithelial ovarian cancer with full-length mesothelin cDNA-transduced dendritic cells. |
| Q84086496 | Survival in rectal cancer is predicted by T cell infiltration of tumour-associated lymphoid nodules |
| Q39317517 | Synergistical toll-like receptors activated dendritic cells induce antitumor effects against carcinoembryonic antigen-expressing colon cancer |
| Q37002795 | T-cell death and cancer immune tolerance |
| Q37051003 | TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours |
| Q41994790 | TLR4 engagement during TLR3-induced proinflammatory signaling in dendritic cells promotes IL-10-mediated suppression of antitumor immunity |
| Q90252257 | TNP-470 skews DC differentiation to Th1-stimulatory phenotypes and can serve as a novel adjuvant in a cancer vaccine |
| Q35516545 | Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model |
| Q36915898 | Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1 |
| Q36975757 | The 'kiss of death' by dendritic cells to cancer cells |
| Q37952783 | The 2011 Nobel Prize in physiology or medicine |
| Q51700278 | The DRAGO gamma camera. |
| Q55220517 | The Role of the Insulin-Like Growth Factor 1 Pathway in Immune Tumor Microenvironment and Its Clinical Ramifications in Gynecologic Malignancies. |
| Q39802340 | The Tat-conjugated N-terminal region of mucin antigen 1 (MUC1) induces protective immunity against MUC1-expressing tumours |
| Q39711562 | The establishment of dendritic cell-tumor fusion vaccines for hormone refractory prostate cancer cell |
| Q37687418 | The evolving role of dendritic cells in cancer therapy |
| Q34010091 | The immunobiology of mushrooms |
| Q36866151 | The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates. |
| Q38902037 | The siRNA cocktail targeting interleukin 10 receptor and transforming growth factor-β receptor on dendritic cells potentiates tumour antigen-specific CD8(+) T cell immunity |
| Q36485047 | Therapeutic dendritic cell vaccine preparation using tumor RNA transfection: a promising approach for the treatment of prostate cancer. |
| Q34202646 | Three-day dendritic cells for vaccine development: Antigen uptake, processing and presentation |
| Q37826217 | Tolerogenic dendritic cells and their potential applications |
| Q38453096 | Tolerogenic dendritic cells show gene expression profiles that are different from those of immunogenic dendritic cells in DBA/1 mice. |
| Q38103222 | Tracking and evaluation of dendritic cell migration by cellular magnetic resonance imaging |
| Q39791562 | Treatment of established colon carcinoma-bearing mice by dendritic cells pulsed with lysates of heat-treated tumor cells |
| Q53109846 | Trial watch: Dendritic cell-based anticancer immunotherapy. |
| Q27024047 | Trial watch: Dendritic cell-based anticancer therapy |
| Q36388529 | Trial watch: Dendritic cell-based interventions for cancer therapy |
| Q42867339 | Trial watch: Dendritic cell-based interventions for cancer therapy |
| Q49592937 | Tumor Immuno-Environment in Cancer Progression and Therapy |
| Q39814228 | Tumor cell lysate-pulsed dendritic cells induce a T cell response against colon cancer in vitro and in vivo |
| Q41977894 | Tumor-associated antigens for specific immunotherapy of prostate cancer |
| Q47689335 | Tumor-derived exosomes educate dendritic cells to promote tumor metastasis via HSP72/HSP105-TLR2/TLR4 pathway |
| Q33763653 | Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism. |
| Q37729243 | Tumour escape mechanisms and their therapeutic implications in combination tumour therapy |
| Q44828889 | Tumour regression induced by co-administration of MIP-3α and CpG in an experimental model of colon carcinoma. |
| Q30846001 | Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients. |
| Q43196387 | Type 2 Bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells |
| Q41271614 | Type I IFN signaling on dendritic cells is required for NK cell-mediated anti-tumor immunity |
| Q37130475 | Type I interferons as vaccine adjuvants against infectious diseases and cancer |
| Q37909430 | Using monoclonal antibodies to stimulate antitumor cellular immunity |
| Q37729146 | Vaccines as early therapeutic interventions for cancer therapy: neutralising the immunosuppressive tumour environment and increasing T cell avidity may lead to improved responses |
| Q26825850 | Vaccines for pancreatic cancer |
| Q39768767 | Vaccines using dendritic cells, differentiated with propofol, enhance antitumor immunity in mice |
| Q38206582 | Various ways to improve whole cancer cell vaccines |
| Q27491330 | Viral Vaccines and CTL Response |
| Q35572421 | Virus-induced tumor inflammation facilitates effective DC cancer immunotherapy in a Treg-dependent manner in mice |
| Q39781975 | Well-defined block copolymers for gene delivery to dendritic cells: probing the effect of polycation chain-length |
| Q57159608 | What's New in Gastric Cancer: The Therapeutic Implications of Molecular Classifications and Future Perspectives |
| Q52716742 | Whole protein and defined CD8(+) and CD4(+) peptides linked to penetratin targets both MHC class I and II antigen presentation pathways. |
| Q36691357 | Whole tumor antigen vaccination using dendritic cells: comparison of RNA electroporation and pulsing with UV-irradiated tumor cells. |
| Q35058235 | Whole tumor antigen vaccines |
| Q38208388 | Wilms' tumor gene 1 immunotherapy in pelvic gynecological malignancies |
| Q53092559 | mRNA Electroporation of Dendritic Cells with WT1, Survivin, and TriMix (a Mixture of caTLR4, CD40L, and CD70). |
Search more.